CD19 and B-cell chronic lymphocytic leukemia: In the initial pilot trials, CD19-directed CAR T cells were also evaluated in patients with relapsed/refractory CLL, but in this setting, CAR T-cell product development was slowed by a lower than expected ability to achieve CR, and a subsequently increased rate of progressive disease.